PON1 and Miyoshi myopathy: Previous work by our group has demonstrated that serum levels of C4, B100 and PON1 are abnormal in patients found to be responders/non-responders to MM therapies, including Thalidomide and Bortezomib (see Additional file 1: Table S1), therefore it would be of interest to see if any correlation existed with bone disease, especially as these proteins appeared in the discovery phase protein list.